CM Core - 90 CT

CM Core by Ortho Molecular Products – Cardiometabolic Support Supplement

CM Core by Ortho Molecular Products is a cardiometabolic support supplement formulated to promote healthy glucose metabolism, metabolic health, and overall cardiovascular support. This targeted blend features well-researched botanicals and antioxidants that work synergistically to support insulin function, healthy blood sugar balance, and cellular protection.

Key CM Core Benefits

• Helps maintain healthy lipid levels
• Provides antioxidant support for cellular health
• Supports healthy inflammatory balance
• Helps maintain healthy lipid levels
• Promotes balanced cardiometabolic function

How CM Core Works

CM Core delivers a combination of clinically studied ingredients that support cardiometabolic wellness with a strong safety profile and minimal side effects. These ingredients work together to promote stable metabolic function without harsh stimulants or aggressive blood sugar–lowering effects:

• Berberine HCl – Helps maintain healthy glucose uptake and insulin signaling while supporting microbial balance.
• Alpha-Lipoic Acid (ALA) – A powerful antioxidant that supports mitochondrial function, healthy glucose utilization, and protection against oxidative stress.

Who Should Use CM Core

CM Core is ideal for individuals seeking a safe, natural way to support joint, bone, and skin health through improved metabolic and cellular function. It is also well-suited for those looking to maintain balanced blood sugar levels, enhance cardiovascular wellness, and support healthy aging.

Supplements support your health but do not replace a balanced diet. Always check with your healthcare practitioner if you have doubts about a new supplement. Or you may book a FREE product consultation with Holistic Health Partners. You may want to look at our other Cardiovascular Health products.

Recommendation: Ortho Molecular Products suggests taking 1 CoQ-10 300mg soft gel capsule per day or as recommended by your healthcare professional.

Serving Size: 1 soft gel capsule
Servings Per Container: 30 or 60

Click here to view Product Info Sheet

References:

1. Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., & Smith, S. C. (2005). Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation, 112, 2735–2752. https://doi.org/10.1161/CIRCULATIONAHA.105.169404
2. Jeong, H. W., Hsu, K. C., Lee, J. W., Ham, M., Huh, J. Y., Shin, H. J., Kim, W. S., & Kim, J. B. (2009). Berberine suppresses proinflammatory responses through AMPK activation in macrophages. American Journal of Physiology-Endocrinology and Metabolism, 296, E955–E964. https://doi.org/10.1152/ajpendo.90778.2008
3. Kemp, B., Stapleton, D., Campbell, D., Chen, Z. P., Murthy, S., Walter, M., Gupta, A., Adams, J., Katsis, F., & van Denderen, B. (2003). AMP-activated protein kinase, super metabolic regulator. Biochemical Society Transactions, 31, 162–168. https://doi.org/10.1042/bst0310162
4. Towler, M. C., & Hardie, D. G. (2007). AMP-activated protein kinase in metabolic control and insulin signaling. Circulation Research, 100, 328–341. https://doi.org/10.1161/01.RES.0000256090.42690.68
5. Lau, C. W., Yao, X. Q., Chen, Z. Y., Ko, W. H., & Huang, Y. (2001). Cardiovascular actions of berberine. Cardiovascular Drug Reviews, 19, 234–244. https://doi.org/10.1111/j.1527-3466.2001.tb00136.x
6. Brusq, J. M., Ancellin, N., Grondin, P., Guillard, R., Martin, S., Saintillan, Y., & Issandou, M. (2006). Inhibition of lipid synthesis through activation of AMP kinase: An additional mechanism for the hypolipidemic effects of berberine. Journal of Lipid Research, 47, 1281–1288. https://doi.org/10.1194/jlr.M500497-JLR200
7. Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., & Pan, H. (2004). Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nature Medicine, 10, 1344–1351. https://doi.org/10.1038/nm1135
8. Derosa, G., D’Angelo, A., Bonaventura, A., Bianchi, L., Romano, D., & Maffioli, P. (2013). Effects of berberine on lipid profile in subjects with low cardiovascular risk. Expert Opinion on Biological Therapy, 13, 475–482. https://doi.org/10.1517/14712598.2013.758709
9. Zhang, H., Wei, J., Xue, R., Wu, J. D., Zhao, W., Wang, Z. Z., Wang, S. K., Zhou, Z. X., Song, D. Q., & Wang, Y. M. (2010). Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism, 59, 285–292. https://doi.org/10.1016/j.metabol.2009.07.029
10. Jäger, S., Handschin, C., Pierre, J. S., & Spiegelman, B. M. (2007). AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α. Proceedings of the National Academy of Sciences, 104, 12017–12022. https://doi.org/10.1073/pnas.0705070104
11. Zhou, L., Yang, Y., Wang, X., Liu, S., Shang, W., Yuan, G., Li, F., Tang, J., Chen, M., & Chen, J. (2007). Berberine stimulates glucose transport through a mechanism distinct from insulin. Metabolism, 56, 405–412. https://doi.org/10.1016/j.metabol.2006.10.013
12. Zhang, Q., Xiao, X., Feng, K., Wang, T., Li, W., Yuan, T., Sun, X., Sun, Q., Xiang, H., & Wang, H. (2011). Berberine moderates glucose and lipid metabolism through multipathway mechanism. Evidence-Based Complementary and Alternative Medicine, 2010, 1–10. https://doi.org/10.1155/2011/924589
13. Shay, K. P., Moreau, R. F., Smith, E. J., Smith, A. R., & Hagen, T. M. (2009). Alpha-lipoic acid as a dietary supplement: Molecular mechanisms and therapeutic potential. Biochimica et Biophysica Acta (BBA)-General Subjects, 1790, 1149–1160. https://doi.org/10.1016/j.bbagen.2009.07.008
14. Lee, W. J., Song, K. H., Koh, E. H., Won, J. C., Kim, H. S., Park, H. S., Kim, M. S., Kim, S. W., Lee, K. U., & Park, J. Y. (2005). α-Lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle. Biochemical and Biophysical Research Communications, 332, 885–891. https://doi.org/10.1016/j.bbrc.2005.05.064
15. Ruderman, N. B., Carling, D., Prentki, M., & Cacicedo, J. M. (2013). AMPK, insulin resistance, and the metabolic syndrome. The Journal of Clinical Investigation, 123, 2764–2772. https://doi.org/10.1172/JCI67227
16. Jacob, S., Ruus, P., Hermann, R., Tritschler, H., Maerker, E., Renn, W., Augustin, H., Dietze, G., & Rett, K. (1999). Oral administration of RAC-α-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: A placebo-controlled pilot trial. Free Radical Biology and Medicine, 27, 309–314. https://doi.org/10.1016/S0891-5849(99)00089-1
17. Packer, L., Witt, E. H., & Tritschler, H. J. (1995). Alpha-lipoic acid as a biological antioxidant. Free Radical Biology and Medicine, 19, 227–250. https://doi.org/10.1016/0891-5849(95)00017-R